A prospective, randomised study to compare goserelin acetate (Zoladex(®)) versus cyproterone acetate (Cyprostat(®)) versus a combination of the two in the treatment of metastatic prostatic carcinoma

European Urology

Volumn 29, Issue 1, 1996, Pages 47-54

  Thorpe, S C ^a   Azmatullah, S ^a   Fellows, G J ^a   Gingell, J C ^a   O'Boyle, P J ^a  

^a Schering Health Care   (United Kingdom)

Author keywords

Androgen suppression; Cyproterone acetate; Goserelin acetate; Prostatic carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYPROTERONE ACETATE; GOSERELIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DYSPNEA; EDEMA; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; LETHARGY; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; SWEATING; TIME; TREMOR;

EID: 0030071467     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000473717     Document Type: Article

References (0)